NCT04829435 - Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

June 1, 2021

Study Completion Date

June 1, 2021

Conditions

HyperuricemiaGout

Interventions

DRUG

ALLN-346

ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration; It is a proprietary enzyme designed to degrade urate in the intestinal tract

DRUG

Placebo

Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules

Trial Locations (1)

45227

Medpace Clinical Pharmacology, Cincinnati